Two Sigma Advisers’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-211,700
| Closed | -$483K | – | 2580 |
|
|
2024
Q2 | $483K | Buy |
211,700
+28,000
| +15% | +$107K | ﹤0.01% | 1896 |
|
|
2024
Q1 | $794K | Buy |
183,700
+50,900
| +38% | +$177K | ﹤0.01% | 1679 |
|
|
2023
Q4 | $405K | Sell |
132,800
-84,600
| -39% | -$159K | ﹤0.01% | 1999 |
|
|
2023
Q3 | $313K | Buy |
217,400
+134,000
| +161% | +$259K | ﹤0.01% | 1966 |
|
|
2023
Q2 | $208K | Sell |
83,400
-190,800
| -70% | -$521K | ﹤0.01% | 2089 |
|
|
2023
Q1 | $735K | Sell |
274,200
-45,600
| -14% | -$219K | ﹤0.01% | 1779 |
|
|
2022
Q4 | $1.74M | Buy |
319,800
+293,400
| +1,111% | +$2.46M | ﹤0.01% | 1311 |
|
|
2022
Q3 | $330K | Sell |
26,400
-5,600
| -18% | -$64K | ﹤0.01% | 2007 |
|
|
2022
Q2 | $158K | Sell |
32,000
-50,200
| -61% | -$278K | ﹤0.01% | 2319 |
|
|
2022
Q1 | $625K | Sell |
82,200
-146,716
| -64% | -$1.39M | ﹤0.01% | 1874 |
|
|
2021
Q4 | $2.34M | Sell |
228,916
-109,800
| -32% | -$1.4M | 0.01% | 1114 |
|
|
2021
Q3 | $4.55M | Sell |
338,716
-204,200
| -38% | -$3.33M | 0.01% | 833 |
|
|
2021
Q2 | $11.9M | Sell |
542,916
-72,000
| -12% | -$1.6M | 0.03% | 499 |
|
|
2021
Q1 | $14.8M | Buy |
614,916
+135,100
| +28% | +$3.14M | 0.04% | 435 |
|
|
2020
Q4 | $8.63M | Buy |
479,816
+370,400
| +339% | +$5.53M | 0.02% | 615 |
|
|
2020
Q3 | $1.26M | Sell |
109,416
-5,400
| -5% | -$89.1K | ﹤0.01% | 1394 |
|
|
2020
Q2 | $2.79M | Buy |
114,816
+8,200
| +8% | +$136K | 0.01% | 1041 |
|
|
2020
Q1 | $1.18M | Buy |
106,616
+47,400
| +80% | +$885K | ﹤0.01% | 1384 |
|
|
2019
Q4 | $1.56M | Buy |
59,216
+41,116
| +227% | +$962K | ﹤0.01% | 1350 |
|
|
2019
Q3 | $412K | Sell |
18,100
-10,400
| -36% | -$328K | ﹤0.01% | 1788 |
|
|
2019
Q2 | $874K | Sell |
28,500
-3,600
| -11% | -$75.8K | ﹤0.01% | 1587 |
|
|
2019
Q1 | $533K | Buy |
32,100
+3,200
| +11% | +$60.7K | ﹤0.01% | 1773 |
|
|
2018
Q4 | $553K | Buy |
28,900
+1,900
| +7% | +$71.2K | ﹤0.01% | 1725 |
|
|
2018
Q3 | $1.41M | Buy |
27,000
+12,800
| +90% | +$698K | ﹤0.01% | 1377 |
|
|
2018
Q2 | $617K | Buy |
+14,200
| New | +$608K | ﹤0.01% | 1834 |
|
Two Sigma Advisers's GTHX Position: Q3 2024 in Review
Two Sigma Advisers sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 211,700 shares — an estimated $483K sold.
Two Sigma Advisers first reported a position in GTHX in Q2 2018 and held it in 25 quarters. The position peaked at $14.8M in Q1 2021. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Two Sigma Advisers reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Two Sigma Advisers sold 211,700 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $483K.
- Two Sigma Advisers first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2018 and held it in 25 quarters.
- Two Sigma Advisers's G1 Therapeutics, Inc. Common Stock position peaked at $14.8M in Q1 2021.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Two Sigma Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.